MEDCLAIR AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.1 SEK | +1.85% |
|
0.00% | -34.45% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 64.12 | 221.9 | 102.6 | 138.4 |
| Enterprise Value (EV) 1 | 64.97 | 203.1 | 99.62 | 135.6 |
| P/E ratio | - | -16.8 x | -20.7 x | -55.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 10 x | 16.7 x | 3.64 x | 3.26 x |
| EV / Revenue | 10.1 x | 15.2 x | 3.54 x | 3.2 x |
| EV / EBITDA | -61.7 x | -22.7 x | 255 x | 73.9 x |
| EV / FCF | -7,21,59,467 x | -3,03,34,337 x | -1,13,12,669 x | 21,12,72,710 x |
| FCF Yield | -0% | -0% | -0% | 0% |
| Price to Book | - | 3.84 x | 1.95 x | 4.39 x |
| Nbr of stocks (in thousands) | 60,492 | 82,492 | 82,492 | 82,492 |
| Reference price 2 | 1.060 | 2.690 | 1.244 | 1.678 |
| Announcement Date | 01/03/21 | 22/03/22 | 20/04/23 | 27/03/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.294 | 5.813 | 6.412 | 13.32 | 28.17 | 42.42 |
| EBITDA 1 | -1.057 | -2.362 | -1.053 | -8.935 | 0.391 | 1.835 |
| EBIT 1 | -1.903 | -3.442 | -1.693 | -12.9 | -3.695 | -2.68 |
| Operating Margin | -35.95% | -59.21% | -26.4% | -96.89% | -13.12% | -6.32% |
| Earnings before Tax (EBT) 1 | -1.908 | -3.588 | -2.009 | -13.01 | -4.987 | -2.775 |
| Net income 1 | -1.908 | -3.588 | -2.009 | -13.02 | -5 | -2.785 |
| Net margin | -36.04% | -61.72% | -31.33% | -97.76% | -17.75% | -6.57% |
| EPS | - | - | - | -0.1600 | -0.0600 | -0.0300 |
| Free Cash Flow | - | - | -0.9004 | -6.694 | -8.806 | 0.6419 |
| FCF margin | - | - | -14.04% | -50.26% | -31.26% | 1.51% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 34.98% |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 06/04/20 | 06/04/20 | 01/03/21 | 22/03/22 | 20/04/23 | 27/03/24 |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|
| Net sales 1 | - | 2.856 | 9.307 |
| EBITDA 1 | - | -2.741 | 3.39 |
| EBIT 1 | - | -4.266 | 1.11 |
| Operating Margin | - | -149.37% | 11.93% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | -2.532 | - | - |
| Net margin | - | - | - |
| EPS | -0.0300 | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 11/08/22 | 03/11/22 | 22/02/23 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.85 | - | - | - |
| Net Cash position 1 | 0.22 | 0.29 | - | 18.8 | 3.01 | 2.81 |
| Leverage (Debt/EBITDA) | - | - | -0.8063 x | - | - | - |
| Free Cash Flow | - | - | -0.9 | -6.69 | -8.81 | 0.64 |
| ROE (net income / shareholders' equity) | -257% | -141% | -9.2% | -26.8% | -9.05% | -5.42% |
| ROA (Net income/ Total Assets) | -23.1% | -31.8% | -3.96% | -14.6% | -3.6% | -2.73% |
| Assets 1 | 8.27 | 11.28 | 50.72 | 89.17 | 139.1 | 101.9 |
| Book Value Per Share | - | - | - | 0.7000 | 0.6400 | 0.3800 |
| Cash Flow per Share | - | - | - | 0.2500 | 0.0500 | 0.0200 |
| Capex | - | - | - | - | 0.31 | 1.03 |
| Capex / Sales | - | - | - | - | 1.09% | 2.43% |
| Announcement Date | 06/04/20 | 06/04/20 | 01/03/21 | 22/03/22 | 20/04/23 | 27/03/24 |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.45% | 86.38L | |
| +3.85% | 3.19TCr | |
| +26.28% | 880.41Cr | |
| +4.16% | 752.58Cr | |
| +19.93% | 546.64Cr | |
| +21.23% | 400.87Cr | |
| -11.51% | 374.18Cr | |
| +10.68% | 372Cr | |
| +11.88% | 330.41Cr | |
| -10.58% | 272.03Cr |
- Stock Market
- Equities
- MCLR Stock
- Financials Medclair AB
